Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
Identifieur interne : 000A17 ( Ncbi/Curation ); précédent : 000A16; suivant : 000A18Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
Auteurs : Clemence Simonin [France] ; M. Tir ; D. Devos ; A. Kreisler ; K. Dujardin ; J. Salleron ; A. Delval ; S. Blond ; L. Defebvre ; A. Destée ; P. KrystkowiakSource :
- Journal of neurology [ 1432-1459 ] ; 2009.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Deep Brain Stimulation, Dyskinesia, Drug-Induced (therapy), Dystonia (chemically induced), Dystonia (therapy), Follow-Up Studies, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (therapy), Severity of Illness Index, Subthalamic Nucleus.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemically induced : Dystonia.
- drug therapy : Parkinson Disease.
- therapy : Dyskinesia, Drug-Induced, Dystonia, Parkinson Disease.
- Deep Brain Stimulation, Follow-Up Studies, Humans, Severity of Illness Index, Subthalamic Nucleus.
Abstract
The purpose of this paper is to describe the effect of 5 years of subthalamic nucleus deep brain stimulation (STN DBS) on levodopa-induced complications, both in everyday life and during an acute challenge with levodopa. Thirty three patients were evaluated during an acute levodopa challenge before surgery and then 1 and 5 years afterwards (both off stim and on stim), using the UPDRS III scale and the CAPSIT-PD scales for dystonia and peak-dose dyskinesia. The UPDRS IV scale was used to assess motor complications in everyday life. The levodopa daily dose and DBS parameters were also recorded. Levodopa-induced complications in everyday life (UPDRS IV) and during an acute levodopa challenge had improved markedly after 1 year (both on and off stim) and still further at 5 years. Peak-dose dyskinesia decreased between the 1- and 5-year measurements. STN DBS decreases levodopa-induced motor complications over the long term. This phenomenon may be explained by (a) overall stabilization of the basal ganglia network and (b) striatal synaptic changes. Our results suggest that DBS leads to both qualitative and quantitative modulations in the corticostriatal loops.
DOI: 10.1007/s00415-009-5195-2
PubMed: 19536584
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B59
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B19
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B19
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000A17
Links to Exploration step
pubmed:19536584Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.</title>
<author><name sortKey="Simonin, Clemence" sort="Simonin, Clemence" uniqKey="Simonin C" first="Clemence" last="Simonin">Clemence Simonin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology and Movement Disorders, Salengro Hospital, EA 2683, Lille University Medical Center, Lille, France. c-simonin@chru-lille.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Movement Disorders, Salengro Hospital, EA 2683, Lille University Medical Center, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tir, M" sort="Tir, M" uniqKey="Tir M" first="M" last="Tir">M. Tir</name>
</author>
<author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name>
</author>
<author><name sortKey="Kreisler, A" sort="Kreisler, A" uniqKey="Kreisler A" first="A" last="Kreisler">A. Kreisler</name>
</author>
<author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name>
</author>
<author><name sortKey="Salleron, J" sort="Salleron, J" uniqKey="Salleron J" first="J" last="Salleron">J. Salleron</name>
</author>
<author><name sortKey="Delval, A" sort="Delval, A" uniqKey="Delval A" first="A" last="Delval">A. Delval</name>
</author>
<author><name sortKey="Blond, S" sort="Blond, S" uniqKey="Blond S" first="S" last="Blond">S. Blond</name>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name>
</author>
<author><name sortKey="Krystkowiak, P" sort="Krystkowiak, P" uniqKey="Krystkowiak P" first="P" last="Krystkowiak">P. Krystkowiak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19536584</idno>
<idno type="pmid">19536584</idno>
<idno type="doi">10.1007/s00415-009-5195-2</idno>
<idno type="wicri:Area/PubMed/Corpus">000B59</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B59</idno>
<idno type="wicri:Area/PubMed/Curation">000B19</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B19</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B19</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B19</idno>
<idno type="wicri:Area/Ncbi/Merge">000A17</idno>
<idno type="wicri:Area/Ncbi/Curation">000A17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.</title>
<author><name sortKey="Simonin, Clemence" sort="Simonin, Clemence" uniqKey="Simonin C" first="Clemence" last="Simonin">Clemence Simonin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology and Movement Disorders, Salengro Hospital, EA 2683, Lille University Medical Center, Lille, France. c-simonin@chru-lille.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Movement Disorders, Salengro Hospital, EA 2683, Lille University Medical Center, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tir, M" sort="Tir, M" uniqKey="Tir M" first="M" last="Tir">M. Tir</name>
</author>
<author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name>
</author>
<author><name sortKey="Kreisler, A" sort="Kreisler, A" uniqKey="Kreisler A" first="A" last="Kreisler">A. Kreisler</name>
</author>
<author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name>
</author>
<author><name sortKey="Salleron, J" sort="Salleron, J" uniqKey="Salleron J" first="J" last="Salleron">J. Salleron</name>
</author>
<author><name sortKey="Delval, A" sort="Delval, A" uniqKey="Delval A" first="A" last="Delval">A. Delval</name>
</author>
<author><name sortKey="Blond, S" sort="Blond, S" uniqKey="Blond S" first="S" last="Blond">S. Blond</name>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name>
</author>
<author><name sortKey="Krystkowiak, P" sort="Krystkowiak, P" uniqKey="Krystkowiak P" first="P" last="Krystkowiak">P. Krystkowiak</name>
</author>
</analytic>
<series><title level="j">Journal of neurology</title>
<idno type="eISSN">1432-1459</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Deep Brain Stimulation</term>
<term>Dyskinesia, Drug-Induced (therapy)</term>
<term>Dystonia (chemically induced)</term>
<term>Dystonia (therapy)</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (therapy)</term>
<term>Severity of Illness Index</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Dystonia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Severity of Illness Index</term>
<term>Subthalamic Nucleus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this paper is to describe the effect of 5 years of subthalamic nucleus deep brain stimulation (STN DBS) on levodopa-induced complications, both in everyday life and during an acute challenge with levodopa. Thirty three patients were evaluated during an acute levodopa challenge before surgery and then 1 and 5 years afterwards (both off stim and on stim), using the UPDRS III scale and the CAPSIT-PD scales for dystonia and peak-dose dyskinesia. The UPDRS IV scale was used to assess motor complications in everyday life. The levodopa daily dose and DBS parameters were also recorded. Levodopa-induced complications in everyday life (UPDRS IV) and during an acute levodopa challenge had improved markedly after 1 year (both on and off stim) and still further at 5 years. Peak-dose dyskinesia decreased between the 1- and 5-year measurements. STN DBS decreases levodopa-induced motor complications over the long term. This phenomenon may be explained by (a) overall stabilization of the basal ganglia network and (b) striatal synaptic changes. Our results suggest that DBS leads to both qualitative and quantitative modulations in the corticostriatal loops.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000A17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:19536584 |texte= Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:19536584" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |